PlasCred Circular Innovations Inc., an Alberta-based plastic recycling company, announced its shares are now listed on the OTCQB Market in the U.S. This listing aims to increase the company's visibility and liquidity among U.S. investors, providing broader access to capital for growth and development. OTCQB is a platform for early-stage companies seeking public trading in North America, which can attract more shareholders and institutional investors. PlasCred's technology converts mixed plastic waste into refined hydrocarbons for use in plastics and energy sectors.
PlasCred Circular Innovations Inc. is now listed on the OTCQB Market. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 02, 2026 03:27 WIB: out of 38 priced US stocks, 7 rose and 30 fell. Notable movers include ECL (Ecolab Inc.) at USD 270.75 with a 1-day change of -1.47% and Pluang order activity of 89% Sell / 11% Buy, AEM (Agnico Eagle Mines Ltd) at USD 180.83 with a 1-day change of -1.33% and 0% Sell / 100% Buy order activity, and ALB (Albemarle Corp.) at USD 104.55 with a 1-day change of -1.16% and 0% Sell / 100% Buy order activity.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
